Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	RESAPP HEALTH LIMITED
ABN	51 094 468 318

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Roger Aston
Date of last notice	11 November 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable	
Date of change	20 December 2019	
No. of securities held prior to change	8,437,500 Ordinary Fully Paid Shares 8,437,500 Performance Shares	
Class	Director Incentive Options (exercisable at \$0.43; expiring 20 December 2022)	
Number acquired	500,000 Director Incentive Options	
Number disposed	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Director Incentive Options issued to provide an incentive and reward for Directors for their contributions to the Company as set out in the Company's Notice of Annual General Meeting.	

⁺ See chapter 19 for defined terms.

No. of securities held after change	Roger Aston: • 500,000 Director Incentive Options Equimetrixs Pty Ltd <newtonwmore fund="" superannuation="">: • 8,437,500 Ordinary Fully Paid Shares • 8,437,500 Performance Shares</newtonwmore>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Director Incentive Options issued as approved by Shareholders at the Annual General Meeting held on 28 November 2019.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 - +Closed period

Were the interests in the securities or contracts detailed	Not applicable
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	RESAPP HEALTH LIMITED
ABN	51 094 468 318

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Chris Ntoumenopoulos
Date of last notice	11 August 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable	
Date of change	20 December 2019	
No. of securities held prior to change	3,109,375 Shares	
Class	Director Incentive Options (exercisable at \$0.43; expiring 20 December 2022)	
Number acquired	500,000 Director Incentive Options	
Number disposed	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Director Incentive Options issued to provide an incentive and reward for Directors for their contributions to the Company as set out in the Company's Notice of Annual General Meeting.	

⁺ See chapter 19 for defined terms.

No. of securities held after change	Sobol Capital Pty Ltd <boc a="" c=""> 3,109,375 Shares Mr Chris Ntoumenopoulos 500,000 Director Incentive Options (\$0.43; expiring 20 December 2022)</boc>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Director Incentive Options issued as approved by Shareholders at the Annual General Meeting held on 28 November 2019.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 - +Closed period

Were the interests in the securities or contracts detailed	Not applicable
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	RESAPP HEALTH LIMITED
ABN	51 094 468 318

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Nathan Buzza
Date of last notice	29/12/2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Allure Capital Pty Ltd <buzza family="" trust=""> - director and beneficiary</buzza>	
Date of change	20 December 2019	
No. of securities held prior to change	Nil	
Class	Director Incentive Options (exercisable at \$0.43; expiring 20 December 2022)	
Number acquired	500,000 Director Incentive Options	
Number disposed	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Director Incentive Options issued to provide an incentive and reward for Directors for their contributions to the Company as set out in the Company's Notice of Annual General Meeting.	
No. of securities held after change	500,000 Director Incentive Options	

⁺ See chapter 19 for defined terms.

Nature of change	Director Incentive Options issued as approved by
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Shareholders at the Annual General Meeting held on 28 November 2019.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written	Not applicable
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	RESAPP HEALTH LIMITED
ABN	51 094 468 318

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Tony Keating
Date of last notice	11 November 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Littles Brook Pty Ltd <the family="" keating="" trust=""> - director and beneficiary</the>	
Date of change	20 December 2019	
No. of securities held prior to change	5,000,000 Options (\$0.025; 2 July 2020) 5,000,000 Options (\$0.05; 2 July 2020) 10,000,000 Options (\$0.10; 2 July 2020)	
Class	Managing Director Options (exercisable at \$0.21; expiring 20 December 2024) Director Incentive Options (exercisable at \$0.43; expiring 20 December 2022)	
Number acquired	975,000 Managing Director Options; and 500,000 Director Incentive Options	
Number disposed	Nil	

⁺ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Managing Director Options issued pursuant to the terms of Dr Keating's contract of employment and as set out in the Company's Notice of Annual General Meeting. Director Incentive Options issued to provide an incentive and reward for Directors for their contributions to the Company as set out in the Company's Notice of Annual General Meeting.	
No. of securities held after change	Anthony Keating	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	Managing Director Options and Director Incentive Options issued as approved by Shareholders at the Company's Annual General Meeting held on 28 November 2019.	

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Part 3 – *Closed period

Were the interests in the securities or contracts detailed	Not applicable
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

⁺ See chapter 19 for defined terms.